Journal
ANNALS OF NEUROLOGY
Volume 88, Issue 5, Pages 1043-1047Publisher
WILEY
DOI: 10.1002/ana.25880
Keywords
-
Categories
Funding
- Swedish Research Council (Vetenskapsradet) [2017-02175]
- UK's Medical Research Council [MC_UU_00019/2]
- Barts Charity
- Forte [2017-02175] Funding Source: Forte
- MRC [MC_UU_00019/2] Funding Source: UKRI
- Swedish Research Council [2017-02175] Funding Source: Swedish Research Council
Ask authors/readers for more resources
Long-term exposure to lipid-lowering drugs might affect Parkinson's disease (PD) risk. We conducted Mendelian randomization analyses where genetic variants indexed expected effects of modulating lipid-lowering drug targets on PD. Statin exposure was not predicted to increase PD risk, although results were not precise enough to support benefits for prevention clearly (odds ratio [OR] = 0.83; 95% confidence interval [CI] = 0.65, 1.07). Other target results were null, except for variants indicating Apolipoprotein-A5 or Apolipoprotein-C3 inhibition might confer protection. These findings suggest peripheral lipid variation may not have a prominent role in PD etiology, but some related drug targets could influence PD via alternate pathways. ANN NEUROL 2020
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
